Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Total Liabilities (2016 - 2026)

Dexcom has reported Total Liabilities over the past 17 years, most recently at $3.7 billion for Q1 2026.

  • Quarterly Total Liabilities fell 18.03% to $3.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Mar 2026, down 18.03% year-over-year, with the annual reading at $3.6 billion for FY2025, 17.98% down from the prior year.
  • Total Liabilities was $3.7 billion for Q1 2026 at Dexcom, up from $3.6 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $4.8 billion in Q3 2025 and troughed at $2.9 billion in Q1 2022.
  • The 5-year median for Total Liabilities is $4.2 billion (2024), against an average of $4.0 billion.
  • Year-over-year, Total Liabilities surged 59.39% in 2023 and then decreased 18.03% in 2026.
  • A 5-year view of Total Liabilities shows it stood at $3.3 billion in 2022, then grew by 28.71% to $4.2 billion in 2023, then rose by 4.43% to $4.4 billion in 2024, then decreased by 17.98% to $3.6 billion in 2025, then increased by 2.3% to $3.7 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Total Liabilities are $3.7 billion (Q1 2026), $3.6 billion (Q4 2025), and $4.8 billion (Q3 2025).